clarithromycin has been researched along with guaifenesin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| DeBartolo, ML; Edmonds, AL; Gustavson, LE; Kaiser, JF; Locke, CS; Schneck, DW | 1 |
| Druce, H; Palmer, R; Ramirez, OE; Rubin, BK | 1 |
| Cave, DR; Grübel, P | 1 |
| Atherton, JC; Barrett, DA; Jenkins, D; Jordan, N; Shaw, PN; Sherwood, PV; Spiller, RC; Wibawa, JI | 1 |
| Majima, Y; Shimizu, S; Shimizu, T | 1 |
| Gabazza, EC; Hattori, R; Majima, Y; Shimizu, S; Shimizu, T | 1 |
| Ishinaga, H; Kitano, M; Majima, Y; Shimizu, T; Takeuchi, K | 1 |
| Hwang, JM; Kim, GH; Kim, WJ; Lee, HS; Lee, HW; Park, DY; Ryu, DY; Song, GA | 1 |
| Kanoh, S; Kubo, K; Rubin, BK; Tanabe, T; Tsushima, K; Yamazaki, Y | 1 |
| Matković-Jožin, S; Perić, A; Vojvodić, D | 1 |
| Shimizu, S; Shimizu, T | 1 |
| Adebisi, AO; Conway, BR | 1 |
| Colombo, G; Haghi, M; King, G; Saadat, A; Traini, D; Young, PM; Zhu, B | 1 |
| Kouzaki, H; Ogawa, T; Omura, S; Shimizu, S; Shimizu, T; Sunazuka, T; Tojima, I | 1 |
| Fujimura, Y; Fujita, M; Haruma, K; Kamada, T; Kimura, T; Matsumoto, H; Murao, T; Nakato, R; Nishibayashi, H; Shiotani, A | 1 |
| Boontida, M; Buraphacheep, JV; Johanna, M; Kristin, F; Maximilian, A; Peter, L; René, H | 1 |
| Chen, X; Hu, H; Hu, P; Li, H; Li, P; Shen, Y; Yuan, G; Zou, Y | 1 |
1 review(s) available for clarithromycin and guaifenesin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for clarithromycin and guaifenesin
| Article | Year |
|---|---|
Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Double-Blind Method; Drug Interactions; Gastric Acidity Determination; Gastric Mucosa; Humans; Male; Middle Aged; Mucus; Omeprazole; Stomach | 1995 |
Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Biological Transport; Clarithromycin; Elasticity; Humans; Methacholine Chloride; Mucus; Nasal Mucosa; Reference Values; Rhinitis; Suppuration; Viscosity | 1997 |
Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the 'regulated on activation, normal T cell expressed and secreted' chemokine in the nasal secretions of patients with nasal polyposis.
Topics: Adult; Aged; Anti-Bacterial Agents; Chemokine CCL5; Clarithromycin; Cytokines; Eosinophil Cationic Protein; Female; Humans; Male; Middle Aged; Mucus; Nasal Mucosa; Nasal Polyps; Prospective Studies; Rhinitis, Allergic, Perennial; T-Lymphocytes; Th2 Cells; Treatment Outcome; Young Adult | 2012 |
15 other study(ies) available for clarithromycin and guaifenesin
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Factors affecting solubility and penetration of clarithromycin through gastric mucus.
Topics: Absorption; Animals; Anti-Bacterial Agents; Biological Assay; Clarithromycin; Gastric Mucins; Gastric Mucosa; Hydrogen-Ion Concentration; Mucus; Permeability; Solubility; Swine; Viscosity | 1998 |
Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.
Topics: Amoxicillin; Animals; Anti-Infective Agents, Local; Clarithromycin; Gastric Acid; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Hydrogen-Ion Concentration; Male; Metronidazole; Mucus; Rats; Rats, Wistar | 2002 |
[Effect of macrolide antibiotics on mucus secretion from cultured epithelial cells of nasal mucosa].
Topics: Anti-Bacterial Agents; Cells, Cultured; Clarithromycin; Depression, Chemical; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Erythromycin; Humans; Josamycin; Mucin 5AC; Mucins; Mucus; Nasal Mucosa | 2001 |
In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Clarithromycin; Disease Models, Animal; Goblet Cells; Humans; In Vitro Techniques; Josamycin; Male; Mucus; Nasal Mucosa; Nose Neoplasms; Penicillins; Rats; Rats, Inbred F344; Respiratory Hypersensitivity; Secretory Rate | 2003 |
Effects of clarithromycin and dexamethasone on mucus production in isografted rat trachea.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clarithromycin; Dexamethasone; Disease Models, Animal; Glucocorticoids; Goblet Cells; Lipopolysaccharides; Male; Metaplasia; Mucus; Rats; Rats, Inbred F344; Secretory Pathway; Severity of Illness Index; Trachea; Tracheitis; Transplantation, Isogeneic; Viscosity | 2011 |
[A case of Menetrier's disease showing mucus bridge observed during endoscopy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Hypertrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Mucus; Pantoprazole; Proton Pump Inhibitors; Tomography, X-Ray Computed | 2011 |
Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.
Topics: Bronchi; Cell Differentiation; Clarithromycin; Enzyme Inhibitors; ErbB Receptors; Flavonoids; Goblet Cells; Heterocyclic Compounds, 3-Ring; Humans; Hyperplasia; Interleukin-13; Isoxazoles; Janus Kinases; Leflunomide; MAP Kinase Signaling System; Mucin 5AC; Mucus; NF-kappa B; Protein Synthesis Inhibitors; Pyridines; Respiratory Mucosa; Signal Transduction; STAT6 Transcription Factor | 2011 |
Azithromycin inhibits mucus hypersecretion from airway epithelial cells.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Azithromycin; Bronchi; Cell Line, Tumor; Clarithromycin; Epithelial Cells; Gene Expression Regulation; Goblet Cells; Humans; Josamycin; Lipopolysaccharides; Mucin 5AC; Mucus; Rats; Trachea | 2012 |
Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus.
Topics: Adhesiveness; Animals; Anti-Bacterial Agents; Cellulose; Chitosan; Clarithromycin; Concanavalin A; Diffusion; Drug Stability; Gastric Juice; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Membranes, Artificial; Microspheres; Mucins; Mucus; Powder Diffraction; Spectroscopy, Fourier Transform Infrared; Swine; X-Ray Diffraction | 2014 |
Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cell Line; Chemistry, Pharmaceutical; Clarithromycin; Dose-Response Relationship, Drug; Electric Impedance; Epithelial Cells; Equipment Design; Humans; Immunologic Factors; Interleukin-8; Lung; Metered Dose Inhalers; Mucus; Permeability; Pharmaceutical Solutions; Pressure; Time Factors | 2015 |
Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cells, Cultured; Clarithromycin; Erythromycin; Goblet Cells; Humans; In Vitro Techniques; Lipopolysaccharides; Mucin 5AC; Mucus; Nasal Mucosa; Rats; Respiratory Mucosa; RNA, Messenger; Tumor Necrosis Factor-alpha | 2015 |
Molecular Detection of H. pylori Using Adherent Gastric Mucous to Biopsy Forceps.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; DNA Primers; DNA, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Mucus; Point Mutation; Polymerase Chain Reaction; RNA, Ribosomal, 16S; RNA, Ribosomal, 23S; Specimen Handling; Surgical Instruments | 2016 |
Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin.
Topics: Administration, Oral; Animals; Caco-2 Cells; Cell Membrane Permeability; Chemistry, Pharmaceutical; Clarithromycin; Excipients; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Mucus; Rats; Rats, Wistar; Solubility | 2017 |
Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Biopolymers; Cell Adhesion; Cell Line, Tumor; Chitosan; Clarithromycin; Glycolipids; Helicobacter pylori; Humans; Mucus; Nanoparticles; Polyethylene Glycols | 2019 |